The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,778.00
Bid: 1,774.00
Ask: 1,774.50
Change: -10.50 (-0.59%)
Spread: 0.50 (0.028%)
Open: 1,796.00
High: 1,808.50
Low: 1,772.50
Prev. Close: 1,788.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK Annual Report 2023 on Form 20-F

5 Mar 2024 17:24

RNS Number : 7075F
GSK PLC
05 March 2024
 

Issued: 5 March 2024, London UK

 

GSK plc 2023 Annual Report on Form 20-F

 

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 5 March 2024 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2023. GSK's 2023 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

A hard copy version of the GSK 2023 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2024.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2023, free of charge, by either:

 

(i)

writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on +44 (0)371 384 2991 (please use the area code if calling from outside the UK);

 

(ii)

writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453 2128 (outside the US); or

 

(iii)

contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

Victoria WhyteCompany Secretary5 March 2024

 

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSQKPBBOBKDKNK
Date   Source Headline
14th Apr 202111:58 amRNSDirector/PDMR Shareholding
12th Apr 20215:32 pmRNSDirector/PDMR Shareholding
12th Apr 20219:48 amRNSDirector/PDMR Shareholding
9th Apr 20215:34 pmRNSDirector/PDMR Shareholding
9th Apr 20211:35 pmRNSDirector/PDMR Shareholding
6th Apr 20212:30 pmRNSDirectorate Change
1st Apr 20213:36 pmRNSTotal Voting Rights
30th Mar 20214:21 pmRNSPublication of 2021 AGM Notice
30th Mar 202111:30 amRNSGSK respiratory product sales reporting changes
24th Mar 202112:30 pmRNSMoncef Slaoui Departs Galvani Bioelectronics
23rd Mar 20214:31 pmRNSDirector/PDMR Shareholding
17th Mar 20216:24 pmRNSChair of Audit & Risk Committee
16th Mar 202111:08 amRNSMedicago and GSK start Phase 3 trial
15th Mar 20215:27 pmRNSDirector/PDMR Shareholding
15th Mar 20217:00 amRNSAnnual Report 2020 on Form 20-F
11th Mar 20212:25 pmRNSDirector/PDMR Shareholding
11th Mar 20217:00 amRNSGSK and Vir share positive VIR-7831 data in COVID
10th Mar 20211:23 pmRNSDirector/PDMR Shareholding
9th Mar 20211:43 pmRNSAnnual Financial Report
2nd Mar 20213:48 pmRNSDirector/PDMR Shareholding
1st Mar 202110:55 amRNSTotal Voting Rights
25th Feb 202112:00 pmRNSGSK announces otilimab data for treatment of COVID
24th Feb 20211:59 pmRNSDirector/PDMR Shareholding
24th Feb 202112:13 pmRNSHolding(s) in Company
23rd Feb 20219:03 amRNSDirector/PDMR Shareholding
22nd Feb 20214:39 pmRNSDirector/PDMR Shareholding
22nd Feb 202110:40 amRNSSanofi and GSK initiate new Phase 2 study
19th Feb 202112:52 pmRNSDirector/PDMR Shareholding
19th Feb 202112:31 pmRNSDirector/PDMR Shareholding
19th Feb 202110:32 amRNSDirector/PDMR Shareholding
18th Feb 20219:59 amRNSDirector/PDMR Shareholding
17th Feb 202112:00 pmRNSGSK/Vir collaborate on antibodies for influenza
17th Feb 20219:00 amRNSDirector/PDMR Shareholding
15th Feb 202110:09 amRNSDirector/PDMR Shareholding
15th Feb 20219:15 amRNSDirector/PDMR Shareholding
12th Feb 20214:26 pmRNSDirector/PDMR Shareholding
12th Feb 20214:23 pmRNSDirector/PDMR Shareholding
12th Feb 20214:20 pmRNSDirector/PDMR Shareholding
10th Feb 20215:05 pmRNSDirector/PDMR Shareholding
10th Feb 20214:54 pmRNSDirector/PDMR Shareholding
4th Feb 202111:15 amRNSDirector/PDMR Shareholding
3rd Feb 202112:00 pmRNSFinal Results
3rd Feb 20217:00 amRNSGSK/CureVac partner on new mRNA Covid-19 vaccines
1st Feb 20212:04 pmRNSTotal Voting Rights
26th Jan 20214:26 pmRNSDirector/PDMR Shareholding
22nd Jan 20217:00 amRNSFDA approves ViiV Healthcare’s Cabenuva for HIV
20th Jan 20214:00 pmRNSDirector/PDMR Shareholding
20th Jan 20213:50 pmRNSDirector/PDMR Shareholding
20th Jan 20213:02 pmRNSDirector/PDMR Shareholding
19th Jan 20216:02 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.